PL406033A1 - Method for diagnosing of thyroid papillous carcinoma, application of microRNA marker for diagnosing of the thyroid carcinoma, assessment of the disease progress and evaluation of patient and/or disease susceptibility to the proposed treatment and diagnostic set containing such markers - Google Patents
Method for diagnosing of thyroid papillous carcinoma, application of microRNA marker for diagnosing of the thyroid carcinoma, assessment of the disease progress and evaluation of patient and/or disease susceptibility to the proposed treatment and diagnostic set containing such markersInfo
- Publication number
- PL406033A1 PL406033A1 PL406033A PL40603313A PL406033A1 PL 406033 A1 PL406033 A1 PL 406033A1 PL 406033 A PL406033 A PL 406033A PL 40603313 A PL40603313 A PL 40603313A PL 406033 A1 PL406033 A1 PL 406033A1
- Authority
- PL
- Poland
- Prior art keywords
- diagnosing
- thyroid
- carcinoma
- mir
- patient
- Prior art date
Links
- 108700011259 MicroRNAs Proteins 0.000 title abstract 6
- 239000002679 microRNA Substances 0.000 title abstract 6
- 238000000034 method Methods 0.000 title abstract 3
- 210000001685 thyroid gland Anatomy 0.000 title abstract 3
- 239000003550 marker Substances 0.000 title abstract 2
- 201000009030 Carcinoma Diseases 0.000 title 1
- 208000033781 Thyroid carcinoma Diseases 0.000 title 1
- 208000024770 Thyroid neoplasm Diseases 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000022602 disease susceptibility Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 238000011156 evaluation Methods 0.000 title 1
- 201000002510 thyroid cancer Diseases 0.000 title 1
- 208000013077 thyroid gland carcinoma Diseases 0.000 title 1
- 239000012472 biological sample Substances 0.000 abstract 3
- 230000003902 lesion Effects 0.000 abstract 3
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 108091061917 miR-221 stem-loop Proteins 0.000 abstract 2
- 108091080321 miR-222 stem-loop Proteins 0.000 abstract 2
- 108091091392 miR-222-1 stem-loop Proteins 0.000 abstract 2
- 108091071617 miR-222-2 stem-loop Proteins 0.000 abstract 2
- 239000013060 biological fluid Substances 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 108091049641 miR-181-1 stem-loop Proteins 0.000 abstract 1
- 108091053227 miR-181a-1 stem-loop Proteins 0.000 abstract 1
- 108091092591 miR-181a-2 stem-loop Proteins 0.000 abstract 1
- 108091085286 miR-181a-3 stem-loop Proteins 0.000 abstract 1
- 108091023796 miR-182 stem-loop Proteins 0.000 abstract 1
- 108091084881 miR-182-1 stem-loop Proteins 0.000 abstract 1
- 108091078636 miR-182-2 stem-loop Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Przedmiotem wynalazku jest sposób diagnozowania zmiany chorobowej, takiej jak nowotwór i/lub zmiana łagodna tarczycy u pacjenta, który to sposób obejmuje: - dostarczanie pochodzącej od pacjenta próbki biologicznej, - określanie ilości jednego lub więcej mikroRNA wybranego z grupy obejmującej miR-146b-5p, miR-146b-3p, miR-221-5p, miR-221-3p, miR-222-5p, miR-222-3p, miR-181a-5p i miR-182-5p w próbce biologicznej, - porównywanie ekspresji mikroRNA z poziomem ekspresji mikroRNA w grupie kontrolnej, - diagnozowanie wystąpienia nowotworu /i/lub zmiany łagodnej u pacjenta, jeśli poziom ekspresji mikroRNA w próbce biologicznej jest zmieniony względem poziomu ekspresji obserwowanej w próbkach płynów biologicznych w grupie kontrolnej. Przedmiotem wynalazku jest także zastosowanie markera mikroRNA do diagnozowania zmiany chorobowej w obrębie tarczycy oraz zestaw do diagnozowania zmiany chorobowej.The subject of the invention is a method for diagnosing a lesion such as cancer and / or benign thyroid in a patient, which method comprises: - providing a patient-derived biological sample, - determining the amount of one or more microRNA selected from the group consisting of miR-146b-5p, miR-146b-3p, miR-221-5p, miR-221-3p, miR-222-5p, miR-222-3p, miR-181a-5p and miR-182-5p in a biological sample, - comparison of microRNA expression with the level of microRNA expression in the control group, - diagnosing the occurrence of a tumor / and / or benign change in a patient if the level of microRNA expression in a biological sample is changed relative to the level of expression observed in biological fluid samples in the control group. The invention also relates to the use of a microRNA marker for diagnosing a thyroid lesion and a kit for diagnosing a lesion.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PL406033A PL406033A1 (en) | 2013-11-14 | 2013-11-14 | Method for diagnosing of thyroid papillous carcinoma, application of microRNA marker for diagnosing of the thyroid carcinoma, assessment of the disease progress and evaluation of patient and/or disease susceptibility to the proposed treatment and diagnostic set containing such markers |
| PCT/IB2014/066057 WO2015071876A2 (en) | 2013-11-14 | 2014-11-14 | Use of microrna markers for diagnosis of thyroid tumors and a diagnostic panel containing such markers. |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PL406033A PL406033A1 (en) | 2013-11-14 | 2013-11-14 | Method for diagnosing of thyroid papillous carcinoma, application of microRNA marker for diagnosing of the thyroid carcinoma, assessment of the disease progress and evaluation of patient and/or disease susceptibility to the proposed treatment and diagnostic set containing such markers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL406033A1 true PL406033A1 (en) | 2015-05-25 |
Family
ID=53058217
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL406033A PL406033A1 (en) | 2013-11-14 | 2013-11-14 | Method for diagnosing of thyroid papillous carcinoma, application of microRNA marker for diagnosing of the thyroid carcinoma, assessment of the disease progress and evaluation of patient and/or disease susceptibility to the proposed treatment and diagnostic set containing such markers |
Country Status (2)
| Country | Link |
|---|---|
| PL (1) | PL406033A1 (en) |
| WO (1) | WO2015071876A2 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4303323A1 (en) | 2022-07-05 | 2024-01-10 | Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie Panstwowy Instytut Oddzial w Gliwicach | A method differentiating benign and malignant tyroid nodules |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8338109B2 (en) | 2006-11-02 | 2012-12-25 | Mayo Foundation For Medical Education And Research | Predicting cancer outcome |
| EP2806054A1 (en) | 2008-05-28 | 2014-11-26 | Genomedx Biosciences Inc. | Systems and methods for expression-based discrimination of distinct clinical disease states in prostate cancer |
| US10407731B2 (en) | 2008-05-30 | 2019-09-10 | Mayo Foundation For Medical Education And Research | Biomarker panels for predicting prostate cancer outcomes |
| US9495515B1 (en) | 2009-12-09 | 2016-11-15 | Veracyte, Inc. | Algorithms for disease diagnostics |
| US10236078B2 (en) | 2008-11-17 | 2019-03-19 | Veracyte, Inc. | Methods for processing or analyzing a sample of thyroid tissue |
| US9074258B2 (en) | 2009-03-04 | 2015-07-07 | Genomedx Biosciences Inc. | Compositions and methods for classifying thyroid nodule disease |
| US8669057B2 (en) | 2009-05-07 | 2014-03-11 | Veracyte, Inc. | Methods and compositions for diagnosis of thyroid conditions |
| US10446272B2 (en) | 2009-12-09 | 2019-10-15 | Veracyte, Inc. | Methods and compositions for classification of samples |
| US20130267443A1 (en) | 2010-11-19 | 2013-10-10 | The Regents Of The University Of Michigan | ncRNA AND USES THEREOF |
| EP2791359B1 (en) | 2011-12-13 | 2020-01-15 | Decipher Biosciences, Inc. | Cancer diagnostics using non-coding transcripts |
| DK3435084T3 (en) | 2012-08-16 | 2023-05-30 | Mayo Found Medical Education & Res | PROSTATE CANCER PROGNOSIS USING BIOMARKERS |
| US11976329B2 (en) | 2013-03-15 | 2024-05-07 | Veracyte, Inc. | Methods and systems for detecting usual interstitial pneumonia |
| US12297505B2 (en) | 2014-07-14 | 2025-05-13 | Veracyte, Inc. | Algorithms for disease diagnostics |
| EP3215170A4 (en) | 2014-11-05 | 2018-04-25 | Veracyte, Inc. | Systems and methods of diagnosing idiopathic pulmonary fibrosis on transbronchial biopsies using machine learning and high dimensional transcriptional data |
| EP3504348B1 (en) | 2016-08-24 | 2022-12-14 | Decipher Biosciences, Inc. | Use of genomic signatures to predict responsiveness of patients with prostate cancer to post-operative radiation therapy |
| EP3571322B9 (en) | 2017-01-20 | 2023-10-04 | VERACYTE SD, Inc. | Molecular subtyping, prognosis, and treatment of bladder cancer |
| EP3593140A4 (en) | 2017-03-09 | 2021-01-06 | Decipher Biosciences, Inc. | PROSTATE CANCER SUB-TYPING TO PREDICT RESPONSE TO HORMONAL THERAPY |
| CA3062716A1 (en) | 2017-05-12 | 2018-11-15 | Decipher Biosciences, Inc. | Genetic signatures to predict prostate cancer metastasis and identify tumor agressiveness |
| US11217329B1 (en) | 2017-06-23 | 2022-01-04 | Veracyte, Inc. | Methods and systems for determining biological sample integrity |
| WO2019028285A2 (en) | 2017-08-04 | 2019-02-07 | Genomedx, Inc. | Use of immune cell-specific gene expression for prognosis of prostate cancer and prediction of responsiveness to radiation therapy |
| KR102649965B1 (en) * | 2019-01-11 | 2024-03-22 | 연세대학교 산학협력단 | Composition for Targeting Medullary Thyroid Cancer |
| RU2705110C1 (en) * | 2019-04-10 | 2019-11-06 | Государственное бюджетное учреждение здравоохранения "Краевая клиническая больница N2" Министерства здравоохранения Краснодарского края | Method for differential diagnosis of thyroid neoplasms |
| CN111286538B (en) * | 2020-02-13 | 2023-04-07 | 朱伟 | Circulating miRNA and carcinoembryonic miRNA markers related to pan-tumor auxiliary diagnosis and application thereof |
| CN114196759B (en) * | 2021-12-31 | 2023-10-20 | 深圳市海普洛斯生物科技有限公司 | Pancreatic cancer biomarker of urine sample and application thereof |
| CN116769922B (en) * | 2023-08-24 | 2023-11-24 | 四川大学华西医院 | Application of reagent for detecting circulating sEV RNA, kit and diagnostic system |
| CN118326047A (en) * | 2024-06-14 | 2024-07-12 | 润安医学科技(苏州)有限公司 | Application of microRNA markers in identification of benign and malignant thyroid nodule |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003300899A1 (en) | 2002-12-12 | 2004-06-30 | Oncotech, Inc. | Genes related to sensitivity and resistance to chemotherapeutic drug treatment |
| US20060160114A1 (en) | 2004-12-02 | 2006-07-20 | Oncotech, Inc. | Reagents and methods for predicting drug resistance |
| CN102943108B (en) | 2006-01-05 | 2014-05-21 | 俄亥俄州立大学研究基金会 | MicroRNA-based methods and compositions for diagnosis, prognosis and treatment of lung cancer |
| US20080076674A1 (en) | 2006-07-06 | 2008-03-27 | Thomas Litman | Novel oligonucleotide compositions and probe sequences useful for detection and analysis of non coding RNAs associated with cancer |
| WO2008046911A2 (en) | 2006-10-20 | 2008-04-24 | Exiqon A/S | Novel human micrornas associated with cancer |
| WO2008154098A2 (en) | 2007-06-07 | 2008-12-18 | Wisconsin Alumni Research Foundation | Reagents and methods for mirna expression analysis and identification of cancer biomarkers |
| WO2009015357A1 (en) | 2007-07-25 | 2009-01-29 | University Of Louisville Research Foundation, Inc. | Exosome-associated microrna as a diagnostic marker |
| WO2009080437A1 (en) | 2007-12-21 | 2009-07-02 | Exiqon A/S | Micro-rna based drug resistance analysis method |
| US20110160290A1 (en) | 2008-05-21 | 2011-06-30 | Muneesh Tewari | Use of extracellular rna to measure disease |
| WO2010145035A1 (en) | 2009-06-19 | 2010-12-23 | Siu K W Michael | Renal cell carcinoma biomarkers |
| EP2341145A1 (en) | 2009-12-30 | 2011-07-06 | febit holding GmbH | miRNA fingerprint in the diagnosis of diseases |
| US20130237590A1 (en) | 2010-07-15 | 2013-09-12 | Mayo Foundation For Medical Education And Research | Assessing thyroid neoplasms |
| EP2772550B1 (en) * | 2010-11-17 | 2017-03-29 | Interpace Diagnostics, LLC | Mirnas as biomarkers for distinguishing benign from malignant thyroid neoplasms |
| AU2012230835B2 (en) * | 2011-03-22 | 2016-05-05 | Cornell University | Distinguishing benign and malignant indeterminate thyroid lesions |
| EP2505664B1 (en) * | 2011-03-30 | 2014-12-03 | Universität Leipzig | Method and means for distinguishing malignant from benign tumor samples, in particular in routine air dried fine needle aspiration biopsy (FNAB) |
| WO2013063544A1 (en) * | 2011-10-27 | 2013-05-02 | Asuragen, Inc. | Mirnas as diagnostic biomarkers to distinguish benign from malignant thyroid tumors |
-
2013
- 2013-11-14 PL PL406033A patent/PL406033A1/en unknown
-
2014
- 2014-11-14 WO PCT/IB2014/066057 patent/WO2015071876A2/en not_active Ceased
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4303323A1 (en) | 2022-07-05 | 2024-01-10 | Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie Panstwowy Instytut Oddzial w Gliwicach | A method differentiating benign and malignant tyroid nodules |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2015071876A2 (en) | 2015-05-21 |
| WO2015071876A3 (en) | 2015-08-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL406033A1 (en) | Method for diagnosing of thyroid papillous carcinoma, application of microRNA marker for diagnosing of the thyroid carcinoma, assessment of the disease progress and evaluation of patient and/or disease susceptibility to the proposed treatment and diagnostic set containing such markers | |
| PL405648A1 (en) | Method for diagnosing primary hepatic carcinoma, application of microRNA marker for diagnosing the lesion within liver, assessment of the progression of disease and evaluation of patient's vulnerability and/or disease to the proposed treatment and diagnostic set containing such same markers | |
| PH12018550037A1 (en) | Quencher containing water-soluble polymer-conjugated nanomaterial and use thereof | |
| CL2008001517A1 (en) | Device for determining the risk of melanoma progression comprising oligonucleotides of one or more melanoma prognostic markers (mpms) chosen from a selection group; procedure for determining the prognosis of melanoma in a patient; Procedure for determining the suitability of a melanoma patient for a drug trial. | |
| BR112014030750A2 (en) | METHOD FOR DIAGNOSIS, PROGNOSIS AND TREATMENT OF LUNG CANCER METASTASIS | |
| MX382266B (en) | METHOD FOR THE DIAGNOSIS, PROGNOSIS AND TREATMENT OF BREAST CANCER METASTASIS. | |
| BR112015008255A2 (en) | Method for the diagnosis, prognosis and treatment of prostate cancer metastasis | |
| BR112018069849A2 (en) | kit, device and method for the detection of early pancreatic cancer or pancreatic cancer precursor lesion | |
| PH12015501868A1 (en) | Inhibitors of histone demethylases | |
| MX2015001081A (en) | Mutations associated with resistance to inhibitors of bruton's tyrosine kinase (btk). | |
| BRPI0901277A2 (en) | biopsy site marker applicator and method | |
| MX360236B (en) | USE OF MARKERS IN THE DIAGNOSIS AND TREATMENT OF CANCER DE PROSTATA. | |
| BR112015012644A2 (en) | method for determining a cancer patient's need, cancer treatment method, pharmaceutical composition, use of a nucleic acid or antibody and kit; | |
| MX2023001945A (en) | Compositions and methods for screening solid tumors. | |
| ATE554389T1 (en) | APEX AS A MARKER FOR LUNG CANCER | |
| EA201490946A1 (en) | METHOD OF QUANTITATIVE EVALUATION OF CANCER TREATMENT | |
| WO2009083780A8 (en) | Breast cancer expression profiling | |
| MY187050A (en) | Cancer cell-specific antibody, anticancer agent, and cancer testing method | |
| BR112015029550A2 (en) | ANTI-VEGF ANTIBODY AND PHARMACEUTICAL COMPOSITION FOR THE PREVENTION, DIAGNOSIS OR TREATMENT OF CANCER OR ANGIOGENESIS-RELATED DISEASE CONTAINING THE SAME | |
| Jiang et al. | Node-extranodal soft tissue stage based on extranodal metastasis is associated with poor prognosis of patients with gastric cancer | |
| WO2014181960A3 (en) | Fluorescent probe sensing tyrosine kinase and use thereof | |
| MY187655A (en) | Use of nucleosome-transcription factor complexes for cancer detection | |
| WO2014020444A3 (en) | Methods and compositions for diagnosis and prognosis in breast cancer | |
| ATE545867T1 (en) | I-PLASTIN TEST METHOD FOR IN VITRO DIAGNOSIS OF COLORECTAL CARCINOMA | |
| MX376087B (en) | MACROCYCLIC RIP2 KINASE INHIBITORS. |